Opeyemi Rebecca Akinajo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Opeyemi Rebecca Akinajo has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Aduragbemi Banke-Thomas
School of Human Sciences, University of Greenwich, London, United Kingdom
5 shared publications Bosede Bukola Afolabi
Department of Obstetrics and Gynaecology Lagos Lagos University of Lagos College of Medicine
3 shared publicationsKristi Sidney Annerstedt
Global Public Health Stockholm Stockholm County Karolinska Institute Department of Global Public Health
3 shared publicationsLenka Beňová
Department of Medicine Idi-Araba Lagos Lagos University Teaching Hospital
3 shared publicationsMobolanle R. Balogun
Department of Community Health & Primary Care Lagos Lagos University of Lagos College of Medicine
3 shared publicationsOchuwa A. Babah
Department of Obstetrics and Gynecology Surulere Lagos 100001 Lagos University Teaching Hospital
3 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by F1000 Research Ltd in VeriXiv
Facilitators and Barriers to Routine Screening for Maternal Anaemia in Nigeria: A Qualitative Study with Providers and Users
- 21 September 2026
- Published by F1000 Research Ltd in VeriXiv
Open AccessFacilitators and Barriers to Routine Screening for Maternal Anaemia in Nigeria: A Qualitative Study with Providers and Users
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 17 (1)
Integrating a single-dose intravenous iron therapy (ferric carboxymaltose) for maternal anaemia in Nigeria: Insights from stakeholder engagement
Background: Maternal anaemia contributes to high maternal morbidity and adverse birth outcomes in Nigeria. Oral iron supplementation is common but limited by poor adherence, side effects and systemic barriers. Ferric carboxymaltose (FCM), a single-dose intravenous iron formulation, offers a promising alternative, yet its routine use in Nigeria remains limited. Policymakers, providers and community leaders influence adoption of health services, making their perspectives key to successful integration. Aim: To explore stakeholder perspectives on integrating FCM for maternal anaemia into routine maternal health services. Setting: The study was conducted in Lagos State, Nigeria. Methods: A qualitative descriptive study was conducted. Thirty-three purposively selected stakeholders participated, representing government agencies, healthcare providers, academic institutions, non-governmental organisations, professional associations and community leaders. Participants were grouped by affiliation and roles to encourage open dialogue. Discussions followed a semi-structured guide, were audio-recorded, transcribed verbatim and thematically analysed using an inductive approach. Results: Three interrelated themes emerged: (1) health workers are not sufficiently prepared for intravenous iron delivery but could be through sensitisation, reorientation and resourcing; (2) sociocultural and religious influences, alongside misconceptions, require targeted community engagement and (3) affordability is a barrier but could be addressed through strategic policy levers. Conclusion: Successful integration of FCM requires investment in health system capacity, sustained community engagement and alignment with financing and policy frameworks. Contribution: The findings illustrate how stakeholder-informed analysis can reveal the practical, cultural and financial conditions necessary for sustainable uptake of FCM, advancing understanding of how maternal health innovations can be integrated within fragmented health systems.
- 1 January 2026
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 17 (1)
Open AccessIntegrating a single-dose intravenous iron therapy (ferric carboxymaltose) for maternal anaemia in Nigeria: Insights from stakeholder engagement
Background: Maternal anaemia contributes to high maternal morbidity and adverse birth outcomes in Nigeria. Oral iron supplementation is common but limited by poor adherence, side effects and systemic barriers. Ferric carboxymaltose (FCM), a single-dose intravenous iron formulation, offers a promising alternative, yet its routine use in Nigeria remains limited. Policymakers, providers and community leaders influence adoption of health services, making their perspectives key to successful integration. Aim: To explore stakeholder perspectives on integrating FCM for maternal anaemia into routine maternal health services. Setting: The study was conducted in Lagos State, Nigeria. Methods: A qualitative descriptive study was conducted. Thirty-three purposively selected stakeholders participated, representing government agencies, healthcare providers, academic institutions, non-governmental organisations, professional associations and community leaders. Participants were grouped by affiliation and roles to encourage open dialogue. Discussions followed a semi-structured guide, were audio-recorded, transcribed verbatim and thematically analysed using an inductive approach. Results: Three interrelated themes emerged: (1) health workers are not sufficiently prepared for intravenous iron delivery but could be through sensitisation, reorientation and resourcing; (2) sociocultural and religious influences, alongside misconceptions, require targeted community engagement and (3) affordability is a barrier but could be addressed through strategic policy levers. Conclusion: Successful integration of FCM requires investment in health system capacity, sustained community engagement and alignment with financing and policy frameworks. Contribution: The findings illustrate how stakeholder-informed analysis can reveal the practical, cultural and financial conditions necessary for sustainable uptake of FCM, advancing understanding of how maternal health innovations can be integrated within fragmented health systems.
- Open Access
- 23 September 2025
- Published by Karolinska Institutet
Beyond effectiveness : implementation factors influencing uptake of IV iron for anaemia in pregnancy in Nigeria
IntroductionAnaemia in pregnancy (AIP) is a major global health challenge, affecting 37% of women worldwide and up to 56% in Nigeria, leading to increased risk of developing complications such as postpartum haemorrhage, maternal death, preterm birth, low birth weight, and long-term neurodevelopmental problems. Beyond these health risks, AIP also causes fatigue and low productivity, adding financial strain on families, especially in contexts where healthcare expenses are largely out-of- pocket.Iron deficiency anaemia (IDA) is the leading cause, yet oral iron, the standard treatment, often fails due to poor adherence from the daily pill burden, forgetfulness and gastrointestinal side effects. Intravenous (IV) iron is a safe, rapid, and effective alternative, particularly for women who cannot tolerate or do not respond to oral iron. Despite its benefits, the use of IV iron remains limited in Nigeria, with little understanding of how to translate its evidence of effectiveness into practice. For widespread use, IV iron must be acceptable to users and providers, feasible to deliver safely with adherence to protocols, and offer better health outcomes at a good value, particularly in a health system dominated by out-of-pocket payments.Aim To increase the understanding of the implementation factors and how they influence key implementation outcomes related to the uptake of IV iron therapy for anaemia in pregnancy in Nigeria.MethodsThis doctoral research was embedded within the context of an open-label Intravenous versus Oral Iron for Iron Deficiency Anaemia in Pregnant Nigerian Women (IVON) trial, a hybrid type 1 effectiveness-implementation study conducted in Kano and Lagos States, Nigeria. The doctoral research, which focused on the implementation arm of the trial, was structured around four mixed-method studies. Study I was an exploratory qualitative study conducted in the pre-implementation phase to explore the acceptability of IV iron among diverse stakeholders. Among purposively selected and consenting participants, 12 focus group discussions (with 140 participants) and 29 key informant interviews were conducted across 10 healthcare facilities. Transcribed data were analysed deductively using the Theoretical Framework of Acceptability. Studies II, III, and IV were conducted during the implementation phase of the IVON trial in 11 facilities.Study II was a repeated cross-sectional survey of trained healthcare providers (HCPs), with a longitudinal component for a subset, to assess how their perceptions of IV iron's acceptability and feasibility varied by provider characteristics and changed over time. The Acceptability of Intervention Measure (AIM) and Feasibility of Intervention Measure (FIM) survey tools were used at baseline (August 2021) and endline (May 2023) to collect data. Analysis was conducted using descriptive statistics, independent and paired t-tests, and ANOVA. In Study III, a sequential explanatory mixed-method design was employed to assess fidelity. Quantitatively, alternate IV iron administrations were directly observed using a checklist, with adherence compared across facilities and states. Qualitatively, 14 in-depth interviews (IDIs) were conducted with HCPs across nine facilities, with transcribed data analysed using deductive thematic analysis based on the Conceptual Framework of Implementation Fidelity. Both qualitative and quantitative data were analysed in NVivo 12 Plus, while Stata version 17.0 was used for the quantitative studies.In Study IV, a decision tree model was used to assess the cost-effectiveness of IV iron (Ferric Carboxymaltose (FCM)) versus oral iron (Ferrous Sulphate (FS)). Costs, health outcomes, and disability-adjusted life years (DALYs) averted were estimated using the IVON Trial and secondary data sources from a limited societal perspective over a one-year horizon. Incremental cost-utility ratios (ICURs) were compared against an opportunity cost-based threshold, with sensitivity analyses conducted to assess parameter uncertainty.ResultsIn Study I, stakeholders highlighted some key factors that contributed to the acceptability of IV iron. The perception of IV iron benefits includes its single-dose administration, which promotes better adherence and rapid health improvements, as well as its potential to avert complications such as the need for blood transfusions. However, some factors hindered acceptance, including misconceptions surrounding IV iron, high out-of-pocket expenses, limited trained HCPs, space and irregular supply. These insights informed strategies to support the implementation of IV iron during the IVON trial.During the implementation phase in Study II, 53 and 39 trained HCPs were surveyed at baseline and endline, respectively, with 20 HCPs participating at both time points. Mean AIM scores differed by state at baseline (p = 0.001) but not at endline, and no differences were found by cadre or facility level. However, mean AIM scores increased significantly over time (p = 0.002). Mean FIM scores did not vary by time, cadre, state, or facility. In Study III, overall fidelity to the protocol was moderate (66%), with the highest rates observed in tertiary facilities (84%) and the lowest in primary facilities (36%). Factors such as working as a team and the readily available charts and protocols facilitated high fidelity. However, individual variations, institutional challenges like heavy workloads and logistical issues such as prolonged patient waiting times contributed to lower fidelity levels. In Study IV, FCM cost more per woman (US$135.50) than FS (US$104.28), but was also more effective, with lower DALYs incurred (0.0111) compared to that of FS (0.0372). The resulting ICUR was US$1,196.06 per DALY averted, which is below the threshold value, indicating that FCM was a cost-effective intervention.ConclusionThe findings from this doctoral research increase the understanding of the factors influencing the implementation of IV iron...
- 23 September 2025
- Published by Karolinska Institutet
Open AccessBeyond effectiveness : implementation factors influencing uptake of IV iron for anaemia in pregnancy in Nigeria
IntroductionAnaemia in pregnancy (AIP) is a major global health challenge, affecting 37% of women worldwide and up to 56% in Nigeria, leading to increased risk of developing complications such as postpartum haemorrhage, maternal death, preterm birth, low birth weight, and long-term neurodevelopmental problems. Beyond these health risks, AIP also causes fatigue and low productivity, adding financial strain on families, especially in contexts where healthcare expenses are largely out-of- pocket.Iron deficiency anaemia (IDA) is the leading cause, yet oral iron, the standard treatment, often fails due to poor adherence from the daily pill burden, forgetfulness and gastrointestinal side effects. Intravenous (IV) iron is a safe, rapid, and effective alternative, particularly for women who cannot tolerate or do not respond to oral iron. Despite its benefits, the use of IV iron remains limited in Nigeria, with little understanding of how to translate its evidence of effectiveness into practice. For widespread use, IV iron must be acceptable to users and providers, feasible to deliver safely with adherence to protocols, and offer better health outcomes at a good value, particularly in a health system dominated by out-of-pocket payments.Aim To increase the understanding of the implementation factors and how they influence key implementation outcomes related to the uptake of IV iron therapy for anaemia in pregnancy in Nigeria.MethodsThis doctoral research was embedded within the context of an open-label Intravenous versus Oral Iron for Iron Deficiency Anaemia in Pregnant Nigerian Women (IVON) trial, a hybrid type 1 effectiveness-implementation study conducted in Kano and Lagos States, Nigeria. The doctoral research, which focused on the implementation arm of the trial, was structured around four mixed-method studies. Study I was an exploratory qualitative study conducted in the pre-implementation phase to explore the acceptability of IV iron among diverse stakeholders. Among purposively selected and consenting participants, 12 focus group discussions (with 140 participants) and 29 key informant interviews were conducted across 10 healthcare facilities. Transcribed data were analysed deductively using the Theoretical Framework of Acceptability. Studies II, III, and IV were conducted during the implementation phase of the IVON trial in 11 facilities.Study II was a repeated cross-sectional survey of trained healthcare providers (HCPs), with a longitudinal component for a subset, to assess how their perceptions of IV iron's acceptability and feasibility varied by provider characteristics and changed over time. The Acceptability of Intervention Measure (AIM) and Feasibility of Intervention Measure (FIM) survey tools were used at baseline (August 2021) and endline (May 2023) to collect data. Analysis was conducted using descriptive statistics, independent and paired t-tests, and ANOVA. In Study III, a sequential explanatory mixed-method design was employed to assess fidelity. Quantitatively, alternate IV iron administrations were directly observed using a checklist, with adherence compared across facilities and states. Qualitatively, 14 in-depth interviews (IDIs) were conducted with HCPs across nine facilities, with transcribed data analysed using deductive thematic analysis based on the Conceptual Framework of Implementation Fidelity. Both qualitative and quantitative data were analysed in NVivo 12 Plus, while Stata version 17.0 was used for the quantitative studies.In Study IV, a decision tree model was used to assess the cost-effectiveness of IV iron (Ferric Carboxymaltose (FCM)) versus oral iron (Ferrous Sulphate (FS)). Costs, health outcomes, and disability-adjusted life years (DALYs) averted were estimated using the IVON Trial and secondary data sources from a limited societal perspective over a one-year horizon. Incremental cost-utility ratios (ICURs) were compared against an opportunity cost-based threshold, with sensitivity analyses conducted to assess parameter uncertainty.ResultsIn Study I, stakeholders highlighted some key factors that contributed to the acceptability of IV iron. The perception of IV iron benefits includes its single-dose administration, which promotes better adherence and rapid health improvements, as well as its potential to avert complications such as the need for blood transfusions. However, some factors hindered acceptance, including misconceptions surrounding IV iron, high out-of-pocket expenses, limited trained HCPs, space and irregular supply. These insights informed strategies to support the implementation of IV iron during the IVON trial.During the implementation phase in Study II, 53 and 39 trained HCPs were surveyed at baseline and endline, respectively, with 20 HCPs participating at both time points. Mean AIM scores differed by state at baseline (p = 0.001) but not at endline, and no differences were found by cadre or facility level. However, mean AIM scores increased significantly over time (p = 0.002). Mean FIM scores did not vary by time, cadre, state, or facility. In Study III, overall fidelity to the protocol was moderate (66%), with the highest rates observed in tertiary facilities (84%) and the lowest in primary facilities (36%). Factors such as working as a team and the readily available charts and protocols facilitated high fidelity. However, individual variations, institutional challenges like heavy workloads and logistical issues such as prolonged patient waiting times contributed to lower fidelity levels. In Study IV, FCM cost more per woman (US$135.50) than FS (US$104.28), but was also more effective, with lower DALYs incurred (0.0111) compared to that of FS (0.0372). The resulting ICUR was US$1,196.06 per DALY averted, which is below the threshold value, indicating that FCM was a cost-effective intervention.ConclusionThe findings from this doctoral research increase the understanding of the factors influencing the implementation of IV iron...
- Open Access
- 23 September 2025
- Published by Karolinska Institutet
Beyond effectiveness : implementation factors influencing uptake of IV iron for anaemia in pregnancy in Nigeria
IntroductionAnaemia in pregnancy (AIP) is a major global health challenge, affecting 37% of women worldwide and up to 56% in Nigeria, leading to increased risk of developing complications such as postpartum haemorrhage, maternal death, preterm birth, low birth weight, and long-term neurodevelopmental problems. Beyond these health risks, AIP also causes fatigue and low productivity, adding financial strain on families, especially in contexts where healthcare expenses are largely out-of- pocket.Iron deficiency anaemia (IDA) is the leading cause, yet oral iron, the standard treatment, often fails due to poor adherence from the daily pill burden, forgetfulness and gastrointestinal side effects. Intravenous (IV) iron is a safe, rapid, and effective alternative, particularly for women who cannot tolerate or do not respond to oral iron. Despite its benefits, the use of IV iron remains limited in Nigeria, with little understanding of how to translate its evidence of effectiveness into practice. For widespread use, IV iron must be acceptable to users and providers, feasible to deliver safely with adherence to protocols, and offer better health outcomes at a good value, particularly in a health system dominated by out-of-pocket payments.Aim To increase the understanding of the implementation factors and how they influence key implementation outcomes related to the uptake of IV iron therapy for anaemia in pregnancy in Nigeria.MethodsThis doctoral research was embedded within the context of an open-label Intravenous versus Oral Iron for Iron Deficiency Anaemia in Pregnant Nigerian Women (IVON) trial, a hybrid type 1 effectiveness-implementation study conducted in Kano and Lagos States, Nigeria. The doctoral research, which focused on the implementation arm of the trial, was structured around four mixed-method studies. Study I was an exploratory qualitative study conducted in the pre-implementation phase to explore the acceptability of IV iron among diverse stakeholders. Among purposively selected and consenting participants, 12 focus group discussions (with 140 participants) and 29 key informant interviews were conducted across 10 healthcare facilities. Transcribed data were analysed deductively using the Theoretical Framework of Acceptability. Studies II, III, and IV were conducted during the implementation phase of the IVON trial in 11 facilities.Study II was a repeated cross-sectional survey of trained healthcare providers (HCPs), with a longitudinal component for a subset, to assess how their perceptions of IV iron's acceptability and feasibility varied by provider characteristics and changed over time. The Acceptability of Intervention Measure (AIM) and Feasibility of Intervention Measure (FIM) survey tools were used at baseline (August 2021) and endline (May 2023) to collect data. Analysis was conducted using descriptive statistics, independent and paired t-tests, and ANOVA. In Study III, a sequential explanatory mixed-method design was employed to assess fidelity. Quantitatively, alternate IV iron administrations were directly observed using a checklist, with adherence compared across facilities and states. Qualitatively, 14 in-depth interviews (IDIs) were conducted with HCPs across nine facilities, with transcribed data analysed using deductive thematic analysis based on the Conceptual Framework of Implementation Fidelity. Both qualitative and quantitative data were analysed in NVivo 12 Plus, while Stata version 17.0 was used for the quantitative studies.In Study IV, a decision tree model was used to assess the cost-effectiveness of IV iron (Ferric Carboxymaltose (FCM)) versus oral iron (Ferrous Sulphate (FS)). Costs, health outcomes, and disability-adjusted life years (DALYs) averted were estimated using the IVON Trial and secondary data sources from a limited societal perspective over a one-year horizon. Incremental cost-utility ratios (ICURs) were compared against an opportunity cost-based threshold, with sensitivity analyses conducted to assess parameter uncertainty.ResultsIn Study I, stakeholders highlighted some key factors that contributed to the acceptability of IV iron. The perception of IV iron benefits includes its single-dose administration, which promotes better adherence and rapid health improvements, as well as its potential to avert complications such as the need for blood transfusions. However, some factors hindered acceptance, including misconceptions surrounding IV iron, high out-of-pocket expenses, limited trained HCPs, space and irregular supply. These insights informed strategies to support the implementation of IV iron during the IVON trial.During the implementation phase in Study II, 53 and 39 trained HCPs were surveyed at baseline and endline, respectively, with 20 HCPs participating at both time points. Mean AIM scores differed by state at baseline (p = 0.001) but not at endline, and no differences were found by cadre or facility level. However, mean AIM scores increased significantly over time (p = 0.002). Mean FIM scores did not vary by time, cadre, state, or facility. In Study III, overall fidelity to the protocol was moderate (66%), with the highest rates observed in tertiary facilities (84%) and the lowest in primary facilities (36%). Factors such as working as a team and the readily available charts and protocols facilitated high fidelity. However, individual variations, institutional challenges like heavy workloads and logistical issues such as prolonged patient waiting times contributed to lower fidelity levels. In Study IV, FCM cost more per woman (US$135.50) than FS (US$104.28), but was also more effective, with lower DALYs incurred (0.0111) compared to that of FS (0.0372). The resulting ICUR was US$1,196.06 per DALY averted, which is below the threshold value, indicating that FCM was a cost-effective intervention.ConclusionThe findings from this doctoral research increase the understanding of the factors influencing the implementation of IV iron...
- 23 September 2025
- Published by Karolinska Institutet
Open AccessBeyond effectiveness : implementation factors influencing uptake of IV iron for anaemia in pregnancy in Nigeria
IntroductionAnaemia in pregnancy (AIP) is a major global health challenge, affecting 37% of women worldwide and up to 56% in Nigeria, leading to increased risk of developing complications such as postpartum haemorrhage, maternal death, preterm birth, low birth weight, and long-term neurodevelopmental problems. Beyond these health risks, AIP also causes fatigue and low productivity, adding financial strain on families, especially in contexts where healthcare expenses are largely out-of- pocket.Iron deficiency anaemia (IDA) is the leading cause, yet oral iron, the standard treatment, often fails due to poor adherence from the daily pill burden, forgetfulness and gastrointestinal side effects. Intravenous (IV) iron is a safe, rapid, and effective alternative, particularly for women who cannot tolerate or do not respond to oral iron. Despite its benefits, the use of IV iron remains limited in Nigeria, with little understanding of how to translate its evidence of effectiveness into practice. For widespread use, IV iron must be acceptable to users and providers, feasible to deliver safely with adherence to protocols, and offer better health outcomes at a good value, particularly in a health system dominated by out-of-pocket payments.Aim To increase the understanding of the implementation factors and how they influence key implementation outcomes related to the uptake of IV iron therapy for anaemia in pregnancy in Nigeria.MethodsThis doctoral research was embedded within the context of an open-label Intravenous versus Oral Iron for Iron Deficiency Anaemia in Pregnant Nigerian Women (IVON) trial, a hybrid type 1 effectiveness-implementation study conducted in Kano and Lagos States, Nigeria. The doctoral research, which focused on the implementation arm of the trial, was structured around four mixed-method studies. Study I was an exploratory qualitative study conducted in the pre-implementation phase to explore the acceptability of IV iron among diverse stakeholders. Among purposively selected and consenting participants, 12 focus group discussions (with 140 participants) and 29 key informant interviews were conducted across 10 healthcare facilities. Transcribed data were analysed deductively using the Theoretical Framework of Acceptability. Studies II, III, and IV were conducted during the implementation phase of the IVON trial in 11 facilities.Study II was a repeated cross-sectional survey of trained healthcare providers (HCPs), with a longitudinal component for a subset, to assess how their perceptions of IV iron's acceptability and feasibility varied by provider characteristics and changed over time. The Acceptability of Intervention Measure (AIM) and Feasibility of Intervention Measure (FIM) survey tools were used at baseline (August 2021) and endline (May 2023) to collect data. Analysis was conducted using descriptive statistics, independent and paired t-tests, and ANOVA. In Study III, a sequential explanatory mixed-method design was employed to assess fidelity. Quantitatively, alternate IV iron administrations were directly observed using a checklist, with adherence compared across facilities and states. Qualitatively, 14 in-depth interviews (IDIs) were conducted with HCPs across nine facilities, with transcribed data analysed using deductive thematic analysis based on the Conceptual Framework of Implementation Fidelity. Both qualitative and quantitative data were analysed in NVivo 12 Plus, while Stata version 17.0 was used for the quantitative studies.In Study IV, a decision tree model was used to assess the cost-effectiveness of IV iron (Ferric Carboxymaltose (FCM)) versus oral iron (Ferrous Sulphate (FS)). Costs, health outcomes, and disability-adjusted life years (DALYs) averted were estimated using the IVON Trial and secondary data sources from a limited societal perspective over a one-year horizon. Incremental cost-utility ratios (ICURs) were compared against an opportunity cost-based threshold, with sensitivity analyses conducted to assess parameter uncertainty.ResultsIn Study I, stakeholders highlighted some key factors that contributed to the acceptability of IV iron. The perception of IV iron benefits includes its single-dose administration, which promotes better adherence and rapid health improvements, as well as its potential to avert complications such as the need for blood transfusions. However, some factors hindered acceptance, including misconceptions surrounding IV iron, high out-of-pocket expenses, limited trained HCPs, space and irregular supply. These insights informed strategies to support the implementation of IV iron during the IVON trial.During the implementation phase in Study II, 53 and 39 trained HCPs were surveyed at baseline and endline, respectively, with 20 HCPs participating at both time points. Mean AIM scores differed by state at baseline (p = 0.001) but not at endline, and no differences were found by cadre or facility level. However, mean AIM scores increased significantly over time (p = 0.002). Mean FIM scores did not vary by time, cadre, state, or facility. In Study III, overall fidelity to the protocol was moderate (66%), with the highest rates observed in tertiary facilities (84%) and the lowest in primary facilities (36%). Factors such as working as a team and the readily available charts and protocols facilitated high fidelity. However, individual variations, institutional challenges like heavy workloads and logistical issues such as prolonged patient waiting times contributed to lower fidelity levels. In Study IV, FCM cost more per woman (US$135.50) than FS (US$104.28), but was also more effective, with lower DALYs incurred (0.0111) compared to that of FS (0.0372). The resulting ICUR was US$1,196.06 per DALY averted, which is below the threshold value, indicating that FCM was a cost-effective intervention.ConclusionThe findings from this doctoral research increase the understanding of the factors influencing the implementation of IV iron...
- Open Access
- 4 July 2025
- Published by F1000 Research Ltd in VeriXiv
Randomized trial of ferric carboxymaltose for postpartum women with moderate to severe anemia (IVON-PP)
- 4 July 2025
- Published by F1000 Research Ltd in VeriXiv
Open AccessRandomized trial of ferric carboxymaltose for postpartum women with moderate to severe anemia (IVON-PP)
- Open Access
- 23 July 2024
- Published by Springer Nature in Implementation Science Communications
- Vol. 5 (1) , 1-14
Implementation fidelity of intravenous ferric carboxymaltose administration for iron deficiency anaemia in pregnancy: a mixed-methods study nested in a clinical trial in Nigeria
Background: Iron deficiency anaemia is common among pregnant women in Nigeria. The standard treatment is oral iron therapy, which can be sub-optimal due to side effects. Intravenous ferric carboxymaltose (FCM) is an evidenced-based alternative treatment with a more favourable side effect profile requiring administration according to a standardized protocol. In this study, we assessed the fidelity of administering a single dose of FCM according to protocol and identified factors influencing implementation fidelity. Methods: We used a mixed-method approach with a sequential explanatory design nested in a clinical trial across 11 facilities in Lagos and Kano States, Nigeria. Guided by a conceptual framework of implementation fidelity, we quantitatively assessed adherence to protocol by directly observing every alternate FCM administration, using an intervention procedure checklist, and compared median adherence by facility and state. Qualitative fidelity assessment was conducted via in-depth interviews with 14 skilled health personnel (SHP) from nine purposively selected health facilities, using a semi-structured interview guide. We analyzed quantitative data using descriptive and inferential statistics in Stata and used thematic analysis to analyze the transcribed interviews in NVivo. Results: A total of 254 FCM administrations were observed across the 11 study sites, with the majority in secondary (63%), followed by primary healthcare facilities (PHCs) (30%). Overall, adherence to FCM administration as per protocol was moderate (63%) and varied depending on facility level. The lowest level of adherence was observed in PHCs (36%). Median, adherence level showed significant differences by facility level (p = 0.001) but not by state (p = 0.889). Teamwork and availability of protocols are facilitation strategies that contributed to high fidelity. However, institutional/ logistical barriers are contextual factors that influenced the varied fidelity levels observed in some facilities. Conclusions: Collaborative teams and access to operating protocols resulted in high fidelity in some facilities. However, in some PHCs, fidelity to FCM was low due to contextual factors and intervention complexities, thereby influencing the quality of delivery. In Nigeria, scale-up of FCM will require attention to staff strength, teamwork and availability of administration protocols, in order to optimize its impact on anaemia in pregnancy.
- 23 July 2024
- Published by Springer Nature in Implementation Science Communications
- Vol. 5 (1) , 1-14
Open AccessImplementation fidelity of intravenous ferric carboxymaltose administration for iron deficiency anaemia in pregnancy: a mixed-methods study nested in a clinical trial in Nigeria
Background: Iron deficiency anaemia is common among pregnant women in Nigeria. The standard treatment is oral iron therapy, which can be sub-optimal due to side effects. Intravenous ferric carboxymaltose (FCM) is an evidenced-based alternative treatment with a more favourable side effect profile requiring administration according to a standardized protocol. In this study, we assessed the fidelity of administering a single dose of FCM according to protocol and identified factors influencing implementation fidelity. Methods: We used a mixed-method approach with a sequential explanatory design nested in a clinical trial across 11 facilities in Lagos and Kano States, Nigeria. Guided by a conceptual framework of implementation fidelity, we quantitatively assessed adherence to protocol by directly observing every alternate FCM administration, using an intervention procedure checklist, and compared median adherence by facility and state. Qualitative fidelity assessment was conducted via in-depth interviews with 14 skilled health personnel (SHP) from nine purposively selected health facilities, using a semi-structured interview guide. We analyzed quantitative data using descriptive and inferential statistics in Stata and used thematic analysis to analyze the transcribed interviews in NVivo. Results: A total of 254 FCM administrations were observed across the 11 study sites, with the majority in secondary (63%), followed by primary healthcare facilities (PHCs) (30%). Overall, adherence to FCM administration as per protocol was moderate (63%) and varied depending on facility level. The lowest level of adherence was observed in PHCs (36%). Median, adherence level showed significant differences by facility level (p = 0.001) but not by state (p = 0.889). Teamwork and availability of protocols are facilitation strategies that contributed to high fidelity. However, institutional/ logistical barriers are contextual factors that influenced the varied fidelity levels observed in some facilities. Conclusions: Collaborative teams and access to operating protocols resulted in high fidelity in some facilities. However, in some PHCs, fidelity to FCM was low due to contextual factors and intervention complexities, thereby influencing the quality of delivery. In Nigeria, scale-up of FCM will require attention to staff strength, teamwork and availability of administration protocols, in order to optimize its impact on anaemia in pregnancy.
- Top Cited PapersOpen Access
- 13 February 2024
- Published by Springer Nature in Reproductive Health
- Vol. 21 (1) , 1-16
Acceptability of IV iron treatment for iron deficiency anaemia in pregnancy in Nigeria: a qualitative study with pregnant women, domestic decision-makers, and health care providers
Background: Anaemia in pregnancy causes a significant burden of maternal morbidity and mortality in sub-Saharan Africa, with prevalence ranging from 25 to 45% in Nigeria. The main treatment, daily oral iron, is associated with suboptimal adherence and effectiveness. Among pregnant women with iron deficiency, which is a leading cause of anaemia (IDA), intravenous (IV) iron is an alternative treatment in moderate or severe cases. This qualitative study explored the acceptability of IV iron in the states of Kano and Lagos in Nigeria. Methods: We purposively sampled various stakeholders, including pregnant women, domestic decision-makers, and healthcare providers (HCPs) during the pre-intervention phase of a hybrid clinical trial (IVON trial) in 10 healthcare facilities across three levels of the health system. Semi-structured topic guides guided 12 focus group discussions (140 participants) and 29 key informant interviews. We used the theoretical framework of acceptability to conduct qualitative content analysis. Results: We identified three main themes and eight sub-themes that reflected the prospective acceptability of IV iron therapy. Generally, all stakeholders had a positive affective attitude towards IV iron based on its comparative advantages to oral iron. The HCPs noted the effectiveness of IV iron in its ability to evoke an immediate response and capacity to reduce anaemia-related complications. It was perceived as a suitable alternative to blood transfusion for specific individuals based on ethicality. However, to pregnant women and the HCPs, IV iron could present a higher opportunity cost than oral iron for the users and providers as it necessitates additional time to receive and administer it. To all stakeholder groups, leveraging the existing infrastructure to facilitate IV iron treatment will stimulate coherence and self-efficacy while strengthening the existing trust between pregnant women and HCPs can avert misconceptions. Finally, even though high out-of-pocket costs might make IV iron out of reach for poor women, the HCPs felt it can potentially prevent higher treatment fees from complications of IDA. Conclusions: IV iron has a potential to become the preferred treatment for iron-deficiency anaemia in pregnancy in Nigeria if proven effective. HCP training, optimisation of information and clinical care delivery during antenatal visits, uninterrupted supply of IV iron, and subsidies to offset higher costs need to be considered to improve its acceptability. Trial registration ISRCTN registry ISRCT N6348 4804. Registered on 10 December 2020 Clinicaltrials.gov NCT04976179. Registered on 26 July 2021
- 13 February 2024
- Published by Springer Nature in Reproductive Health
- Vol. 21 (1) , 1-16
Top Cited PapersOpen AccessAcceptability of IV iron treatment for iron deficiency anaemia in pregnancy in Nigeria: a qualitative study with pregnant women, domestic decision-makers, and health care providers
Background: Anaemia in pregnancy causes a significant burden of maternal morbidity and mortality in sub-Saharan Africa, with prevalence ranging from 25 to 45% in Nigeria. The main treatment, daily oral iron, is associated with suboptimal adherence and effectiveness. Among pregnant women with iron deficiency, which is a leading cause of anaemia (IDA), intravenous (IV) iron is an alternative treatment in moderate or severe cases. This qualitative study explored the acceptability of IV iron in the states of Kano and Lagos in Nigeria. Methods: We purposively sampled various stakeholders, including pregnant women, domestic decision-makers, and healthcare providers (HCPs) during the pre-intervention phase of a hybrid clinical trial (IVON trial) in 10 healthcare facilities across three levels of the health system. Semi-structured topic guides guided 12 focus group discussions (140 participants) and 29 key informant interviews. We used the theoretical framework of acceptability to conduct qualitative content analysis. Results: We identified three main themes and eight sub-themes that reflected the prospective acceptability of IV iron therapy. Generally, all stakeholders had a positive affective attitude towards IV iron based on its comparative advantages to oral iron. The HCPs noted the effectiveness of IV iron in its ability to evoke an immediate response and capacity to reduce anaemia-related complications. It was perceived as a suitable alternative to blood transfusion for specific individuals based on ethicality. However, to pregnant women and the HCPs, IV iron could present a higher opportunity cost than oral iron for the users and providers as it necessitates additional time to receive and administer it. To all stakeholder groups, leveraging the existing infrastructure to facilitate IV iron treatment will stimulate coherence and self-efficacy while strengthening the existing trust between pregnant women and HCPs can avert misconceptions. Finally, even though high out-of-pocket costs might make IV iron out of reach for poor women, the HCPs felt it can potentially prevent higher treatment fees from complications of IDA. Conclusions: IV iron has a potential to become the preferred treatment for iron-deficiency anaemia in pregnancy in Nigeria if proven effective. HCP training, optimisation of information and clinical care delivery during antenatal visits, uninterrupted supply of IV iron, and subsidies to offset higher costs need to be considered to improve its acceptability. Trial registration ISRCTN registry ISRCT N6348 4804. Registered on 10 December 2020 Clinicaltrials.gov NCT04976179. Registered on 26 July 2021
- Open Access
- 7 March 2023
- Published by Springer Nature in Implementation Science Communications
- Vol. 4 (1) , 1-11
A continuous quality improvement strategy to strengthen screening practices and facilitate the routine use of intravenous iron for treating anaemia in pregnant and postpartum women in Nigeria: a study protocol
Background: Pregnancy-related anaemia is a public health challenge across Africa. Over 50% of pregnant women in Africa get diagnosed with this condition, and up to 75% of these are caused by iron deficiency. The condition is a significant contributor to the high maternal deaths across the continent and, in particular, Nigeria, which accounts for about 34% of global maternal deaths. Whereas oral iron is the mainstay treatment for pregnancy-related anaemia in Nigeria, this treatment is not very effective given the slow absorption of the medication, and its gastrointestinal adverse effects which lead to poor compliance by women. Intravenous iron is an alternative therapy which can rapidly replenish iron stores, but fears of anaphylactic reactions, as well as several misconceptions, have inhibited its routine use. Newer and safer intravenous iron formulations, such as ferric carboxymaltose, present an opportunity to overcome some concerns relating to adherence. Routine use of this formulation will, however, require addressing misconceptions and systemic barriers to adoption in the continuum of care of obstetric women from screening to treatment. This study aims to test the options to strengthen routine screening for anaemia during and immediately after pregnancy, as well as evaluate and improve conditions necessary to deliver ferric carboxymaltose to pregnant and postpartum women with moderate to severe anaemia. Methods: This study will be conducted in a cluster of six health facilities in Lagos State, Nigeria. The study will employ continuous quality improvement through the Diagnose-Intervene-Verify-Adjust framework and Tanahashi’s model for health system evaluation to identify and improve systemic bottlenecks to the adoption and implementation of the intervention. Participatory Action Research will be employed to engage health system actors, health services users, and other stakeholders to facilitate change. Evaluation will be guided by the consolidated framework for implementation research and the normalisation process theory. Discussion: We expect the study to evolve transferable knowledge on barriers and facilitators to the routine use of intravenous iron that will inform scale-up across Nigeria, as well as the adoption of the intervention and strategies in other countries across Africa.
- 7 March 2023
- Published by Springer Nature in Implementation Science Communications
- Vol. 4 (1) , 1-11
Open AccessA continuous quality improvement strategy to strengthen screening practices and facilitate the routine use of intravenous iron for treating anaemia in pregnant and postpartum women in Nigeria: a study protocol
Background: Pregnancy-related anaemia is a public health challenge across Africa. Over 50% of pregnant women in Africa get diagnosed with this condition, and up to 75% of these are caused by iron deficiency. The condition is a significant contributor to the high maternal deaths across the continent and, in particular, Nigeria, which accounts for about 34% of global maternal deaths. Whereas oral iron is the mainstay treatment for pregnancy-related anaemia in Nigeria, this treatment is not very effective given the slow absorption of the medication, and its gastrointestinal adverse effects which lead to poor compliance by women. Intravenous iron is an alternative therapy which can rapidly replenish iron stores, but fears of anaphylactic reactions, as well as several misconceptions, have inhibited its routine use. Newer and safer intravenous iron formulations, such as ferric carboxymaltose, present an opportunity to overcome some concerns relating to adherence. Routine use of this formulation will, however, require addressing misconceptions and systemic barriers to adoption in the continuum of care of obstetric women from screening to treatment. This study aims to test the options to strengthen routine screening for anaemia during and immediately after pregnancy, as well as evaluate and improve conditions necessary to deliver ferric carboxymaltose to pregnant and postpartum women with moderate to severe anaemia. Methods: This study will be conducted in a cluster of six health facilities in Lagos State, Nigeria. The study will employ continuous quality improvement through the Diagnose-Intervene-Verify-Adjust framework and Tanahashi’s model for health system evaluation to identify and improve systemic bottlenecks to the adoption and implementation of the intervention. Participatory Action Research will be employed to engage health system actors, health services users, and other stakeholders to facilitate change. Evaluation will be guided by the consolidated framework for implementation research and the normalisation process theory. Discussion: We expect the study to evolve transferable knowledge on barriers and facilitators to the routine use of intravenous iron that will inform scale-up across Nigeria, as well as the adoption of the intervention and strategies in other countries across Africa.